デフォルト表紙
市場調査レポート
商品コード
967426

免疫療法薬の世界市場 (2020年~2027年)

Global Immunotherapy Drugs Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.66円
免疫療法薬の世界市場 (2020年~2027年)
出版日: 2021年04月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の免疫療法薬市場は、標的療法の普及や患者の長寿化、生活習慣病の有病率の上昇などの要因に支えられて、今後も拡大傾向が続く見通しです。従来型の治療法よりも標的療法の利用が拡大していることも、市場成長の大きな要因となっています。

当レポートでは、世界の免疫療法向け治療薬の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、薬剤の種類別・治療領域別・流通チャネル別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。

目次

第1章 世界の免疫療法薬市場:分析手法・範囲

第2章 世界の免疫療法薬市場:市場の定義と概要

第3章 世界の免疫療法薬市場:エグゼクティブサマリー

第4章 世界の免疫療法薬市場:市場力学

  • 市場への影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響力の分析

第5章 世界の免疫療法薬市場:産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • 価格分析
  • 医療費償還の分析
  • アンメットニーズ

第6章 世界の免疫療法薬市場:新型コロナウイルス感染症 (COVID-19) の分析

  • COVID-19の市場への影響の分析
    • 「ビフォーコロナ」/過去の市場シナリオ
    • 「ウィズコロナ」/現在の市場シナリオ
    • 「アフターコロナ」/将来の市場シナリオ
  • COVID-19流行中の価格動向
  • 需要・供給の変動域
  • 感染拡大時の市場に対する政府の取り組み
  • メーカー各社の戦略展開状況
  • 結論

第7章 世界の免疫療法薬市場:薬剤の種類別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):薬剤の種類別
  • 市場求心力指数:薬剤の種類別
    • モノクローナル抗体
    • ワクチン
    • インターフェロンアルファ/ベータ
    • インターロイキンチェックポイント阻害剤
    • その他

第8章 世界の免疫療法薬市場:治療領域別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):治療領域別
  • 市場求心力指数:治療領域別
    • がん
    • 自己免疫疾患/炎症性疾患
    • 感染症
    • その他

第9章 世界の免疫療法薬市場:流通チャネル別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):流通チャネル別
  • 市場求心力指数:流通チャネル別
    • 病院
    • クリニック
    • がん調査センター
    • その他

第10章 世界の免疫療法薬市場:地域別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):地域別
  • 市場求心力指数:地域別
  • 北米
    • イントロダクション
    • 域内市場の固有の動向
    • 市場規模の分析と対前年成長率 (YoY):薬剤の種類別
    • 市場規模の分析と対前年成長率 (YoY):治療領域別
    • 市場規模の分析と対前年成長率 (YoY):流通チャネル別
    • 市場規模の分析と対前年成長率 (YoY):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の免疫療法薬市場:競合情勢

  • 競争シナリオ
  • 市場ポジショニング/シェア分析
  • 企業合併・買収 (M&A) の分析

第12章 世界の免疫療法薬市場:企業プロファイル

  • Daiichi Sankyo Company
    • 企業概要
    • 製品のポートフォリオ/概略
    • 近年の動向
    • 財務分析:概要
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc. AbbVie, Inc.
  • Amgen, Inc.
  • Merck & Co., Inc.
  • Alligator Bioscience
  • UbiVac
  • Bristol-Myers Squibb
  • Novartis International AG
  • AstraZeneca Plc.
  • その他の企業

第13章 世界の免疫療法薬市場:重要考察

第14章 DataM Intelligenceについて

目次

Global Immunotherapy Drugs Market is segmented By Drug Type (Monoclonal Antibodies, Vaccines (Preventive Vaccines, Therapeutic Vaccines), Interferons Alpha and Beta, Interleukins Checkpoint Inhibitors, Other), By Therapy Area (Cancer (Solid Tumor, Malignant), Autoimmune and Inflammatory Diseases, Infectious Diseases, Other), By Distribution Channel (Hospitals, Clinics, Cancer Research Center, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Immunotherapy Drugs Market is expected to grow at a high CAGR of 10.1% during the forecasting period (2020-2027).

Immunotherapy is treatment that uses a person's own immune system to fight cancer. Immunotherapy can boost or change how the immune system works so it can find and attack cancer cells. Immunotherapy drugs are used to enhance or suppress the immune system of the body. They are mostly used in the treatment of cancer and act by stimulating the immune system of the body and generate an immune response aiding the production of antibodies. Antibodies produced against antigen kill the cancerous or tumor cells. The global immunotherapy drugs market is expected to grow significant growth during the forecast period due to increase in incidence of cancer.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The global immunotherapy drugs  market growth is driven by the increasing adoption of targeted therapies, increase in life span of patients, and high prevalence of lifestyle diseases.

The global immunotherapy drugs market is driven by the rising incidences of cancer

The major factor for most cancers is the rise in geriatric population, as cancer rates increase with age. According to a report from WHO in 2015, approximately 50% of people treated with cancer in the U.K. are over the age of 60. Obesity, change in lifestyle, smoking, and eating habits are other important factors which are increasing the number of cancer patients. People are favoring toward cancer treatments with lesser side effects. This factor is likely to propel the growth of the global immunotherapy drugs market in the next few years, as immunotherapy drugs are found to have lesser side effects as compared to other treatments. Rise in opportunities in developing markets and immunotherapy as a substitute to chemotherapy for first line treatment are drivers which are expected to propel the growth of the market. In addition, quicker drug approval process and high prevalence rate of lifestyle diseases are projected to drive the market growth during the forecast period..

The rising adoption of targeted therapy over traditional therapy

The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars. Furthermore, immunotherapy drugs is widely used in cancer treatment.  

For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.

Risks associated with use is likely to hinder the market growth

For patients receiving immunotherapy drugs that are given intravenously, the most common side effects include skin reactions at the site of the injection, such as pain, swelling, and soreness. Some immunotherapy drugs may cause severe or even fatal allergic reactions, though this is rare. This factor is hindering the growth of the market. This factor is hindering the growth of the market in the forecast period.

COVID-19 Impact Analysis

The havoc caused by the COVID-19 pandemic continues to disrupt daily life, but its reach goes deeper and further with mounting consequences for cancer patients who need ongoing treatment. Hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease, forcing cancer patients to weigh the potential benefit of a face-to-face visit and treatment with the risks of catching the virus.   The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows. This factor will hinder the growth of the immunotherapy drugs market.

Segment Analysis

By drug type, the immunotherapy drugs market is classified into monoclonal antibodies, vaccines (preventive vaccines, therapeutic vaccines), interferons alpha and beta, interleukins, checkpoint inhibitors, other.

Monoclonal Antibodies segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)  

Monoclonal antibodies (mAbs), a type of mono-specific antibodies, are comprised of identical antibody molecules and are produced by a single clone of cells or cell line. Monoclonal antibodies have brought about a fundamental change in pharmaceutical and biotechnology sectors and in the future too are slated to play a crucial role in clinical protocol with further development of these molecular agents. Monoclonal antibodies find application in the treatment of a variety of diseases, particularly autoimmune, cancer, and inflammatory diseases. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies segment growth over the forecast period. Additionally, the increasing drug approvals and launches of novel monoclonal antibodies for various diseases treatments such as cancer, robust research, and development of monoclonal antibodies for multiple diseases and technologies such as the advent of mammalian cell culture, process, and formulation technology is expected to be significant market opportunities.

On the basis of therapy area, the immunotherapy drugs market is classified into cancer ( solid tumor, malignant), autoimmune and inflammatory diseases, infectious diseases, other.

The cancer are expected to dominate the Immunotherapy Drugs market during the forecast period

Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow. There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators.​ In 2005, 7.6 million people died of cancer out of 58 million deaths worldwide. Based on projections, cancer deaths will continue to rise with an estimated 9 million people dying from cancer in 2015, and 11.4 million dying in 2030. The increasing trend of cancer incidence has forced the humanity to work more on the cancer prevention and treatments.

According to a report from WHO in 2015, approximately 50% of people treated with cancer in the U.K. are over the age of 60. Obesity, change in lifestyle, smoking, and eating habits are other important factors which are increasing the number of cancer patients. People are favoring toward cancer treatments with lesser side effects. This factor is likely to propel the growth of segment.

Solid Tumor : Solid tumors include cancers of the brain, ovary, breast, colon and other tissues. These cancer stem cells are thought to divide to produce the bulk of the cells that make up the tumor. In 2005, 7.6 million people died of cancer out of 58 million deaths worldwide. More than 70% of all cancer deaths occur in low and middle-income countries, where resources available for prevention, diagnosis and treatment of cancer are limited or nonexistent. Based on projections, cancer deaths will continue to rise with an estimated 9 million people dying from cancer in 2015, and 11.4 million dying in 2030.

Malignant : Malignant refers to cancer cells that can invade and kill nearby tissue and spread to other parts of the body. Malignant cancer is any form of cancer or growth that can spread to other parts of the body in a process called metastasis. It is compared to benign growths or cancers that do not easily spread to other parts of the body and may be much easier to treat. Malignant can be defined as progressive, bad, and resistant to any form of treatment, but it shouldn't be understood as necessarily fatal. Caught early, many forms of cancer can be treated through removal of tumors and additional measures like chemotherapy and radiation.

Geographical Analysis

North America region holds the largest market share global immunotherapy drugs market

North America region is dominating the global immunotherapy drugs  market accounted for the largest market share in 2019, ue to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.

 According to the estimates of the American Cancer Society, in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.​

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy drugs market in the United States.

Competitive Landscape

The immunotherapy drugs market is moderately competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc. AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc, Daiichi Sankyo Company. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the immunotherapy drugs market globally.    

Daiichi Sankyo Company

Overview: Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.  

Product Portfolio: The Company's portfolio comprised of prasugrel, an antiplatelet agent, denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment.

Key Development: In August 2, 2019, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)  announced that the U.S. Food and Drug Administration (FDA) approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare, non-malignant tumor that affects small and large joints.

Why Purchase the Report?

Visualize the composition of the immunotherapy drugs market segmentation by drug type, therapy area, end user highlighting the key commercial assets and players.

Identify commercial opportunities in immunotherapy drugs market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of immunotherapy drugs market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global immunotherapy drugs market report would provide an access to an approx. 63 market data table, 57 figures and 250 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Related Topic's

Generic Drugs Market

Cancer Immunotherapy Market

Table of Contents

Table of Contents

Immunotherapy Drugs Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Immunotherapy Drugs Market - Market Definition and Overview

Immunotherapy Drugs Market - Executive Summary

Market Snippet by  Drug Type

Market snippet by Therapy Area

Market snippet by Distribution Channel

Market Snippet by Region

Immunotherapy Drugs  Market-Market Dynamics

Market Impacting Factors

Drivers

Increasing adoption of immunotherapy drugs over conventional treatment regimens

Rising prevalence of cancer and autoimmune & infectious diseases

Restraints:

Timeline issues, side-effects, and manufacturing complexities

Risks associated to the use of Immunotherapy Drugs

Opportunity

Impact Analysis

Immunotherapy Drugs Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Immunotherapy Drugs  Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Immunotherapy Drugs Market - By Drug Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment

Market Attractiveness Index, By Drug  Type Segment

Monoclonal Antibodies*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Vaccines

Preventive Vaccines

 Therapeutic Vaccines

 Interferons Alpha and Beta

 Interleukins Checkpoint Inhibitors

 Other

Immunotherapy Drugs Market - By Therapy Area

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Attractiveness Index, By Therapy Area

Cancer *

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

 Solid Tumor

 Malignant

Autoimmune and Inflammatory Diseases

 Infectious Diseases

 Other

Immunotherapy Drugs Market - By Distribution Channel

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

Market Attractiveness Index, By Distribution Channel Segment

Hospitals *

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Clinics

 Cancer Research Center

 Other

Immunotherapy Drugs Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Immunotherapy Drugs Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Immunotherapy Drugs Market- Company Profiles

Daiichi Sankyo Company  *

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

F. Hoffmann-La Roche AG

 GlaxoSmithKline plc. AbbVie, Inc.

 Amgen, Inc.

 Merck & Co., Inc.

 Alligator Bioscience

 UbiVac

 Bristol-Myers Squibb

 Novartis International AG

AstraZeneca Plc.

Immunotherapy Drugs Market - Premium Insights

Immunotherapy Drugs Market - DataM

Appendix

About Us and Services

Contact Us (List Not Exhaustive)

Suggestions for Related Market Report:

3D Printed Drugs Market

Pulmonary Drugs Market

Migraine Drugs Market

Orphan Drugs Market

AMD Drugs Market